Covid-19 associated autoimmune thrombotic thrombocytopenic purpura: Report of a case

Hindilerden, Fehmi; Yonal-Hindilerden, Ipek; Akar, Emre; Kart-Yasar, Kadriye

doi:10.1016/j.thromres.2020.07.005

Cited by 55 publications

(66 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…ADAMTS13 antigen activity level and antibody confirmed the diagnosis of TTP. She received daily plasma exchange and methylprednisolone [40] . Capecchi et al reported a 55-year-old woman with a previous TTP history associated with bacterial pneumonia, thirty years ago.…”

Section: Discussionmentioning

confidence: 99%

COVID-19 associated thrombotic thrombocytopenic purpura (TTP) ; A case series and mini-review

Tehrani

Darnahal

Vaezi

et al. 2021

International Immunopharmacology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

COVID-19 associated thrombotic thrombocytopenic purpura (TTP) ; A case series and mini-review

Tehrani

Darnahal

Vaezi

et al. 2021

International Immunopharmacology

View full text Add to dashboard Cite

“…vWF is released from both endothelial cells and platelet storage granules and mediates platelet adhesion to the endothelium. Evaluation of circulating vWF multimers in patients with COVID-19 might be informative because COVID-19 pathology has signatures of thrombotic thrombocytopenia purpura, which is characterized by thrombocytopenia, microthrombi, endothelial cell dysregulation and increased circulating levels of vWF multimers 224,225 . Elevated circulating levels of vWF seem to have prognostic relevance in COVID-19, being associated with severe disease 69 .…”

Section: Cardiovascular Risk Factors and Covid-19mentioning

confidence: 99%

Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation

et al. 2020

View full text Add to dashboard Cite

The unprecedented outbreak of coronavirus disease 2019 (COVID-19) was declared a pandemic by the WHO, with >34 million people infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, and with>1 million COVID-19-related deaths worldwide 1. COVID-19 can lead to a disease spectrum ranging from mild respiratory symptoms to acute respiratory distress syndrome (ARDS) and death 2-4. SARS-CoV-2 is now the third highly pathogenic and transmissible coronavirus identified in humans. Human coronaviruses were first dis covered in the 1960s 5 , but it was not until the 21st century that coronaviruses were recognized as major threats to public health. SARS-CoV 6-9 , Middle East respiratory syndrome coronavirus (MERS-CoV) 10 and SARS-CoV-2 all cause severe respiratory tract infections and have been associated with global pandemics. SARS-CoV was first reported in China in 2003 and infected >8,000 indivi duals, causing 774 deaths worldwide 11. A decade later, MERS was first reported in Saudi Arabia and infected >2,494 individuals and caused 858 deaths, with an extremely high death rate of 34% in part owing to the lack of effective therapies 12,13. SARS-CoV, MERS-CoV and SARS-CoV-2 belong to the Betacoronavirus genus, which is one of four genera of coronavirus 14. Phylogenetic analysis revealed that SARS-CoV-2 is closely related to two bat-derived SARS-like coronaviruses, bat-SL-CoVZC45 and bat-SL-CoVZXC21 (with around 88% sequence identity), SARS-CoV (approximately 79% sequence identity) and MERS-CoV (approximately 50% sequence identity) 15. Homology modelling revealed that the receptor-binding domain structures in SARS-CoV and SARS-CoV-2 are similar, despite some amino acid variations 15. MERS-CoV infects human cells by binding to the dipeptidyl peptidase 4 receptor 16 , whereas both SARS-CoV 17 and SARS-CoV-2 (refs 18,19) use angiotensin-converting enzyme 2 (ACE2) as a receptor to infect cells. For SARS-CoV-2 infection, in addition to ACE2, one or more proteases including transmembrane protease serine 2 (TMPRSS2), basigin (also known as CD147) and potentially cathepsin B or cathepsin L are required 18,19. Acute respiratory distress syndrome (ArDs). A syndrome characterized by severe acute respiratory failure arising from inflammation and fluid build-up in the lungs.

show abstract

“…However, viral infections are well described triggers of TTP cases [ 2 ], and SARS-CoV2 have been described in correlation with different autoimmune and inflammatory diseases in both children and adults [ 3 ]. Finally, two cases of TTP were recently reported in patients diagnosed with COVID-19 [ 4 , 5 ]. In both cases, thrombotic microangiopathy presented six days after initial symptoms of viral infection and COVID pneumonia was mild.…”

mentioning

confidence: 99%

A case of thrombotic thrombocytopenic purpura associated with COVID-19

Nicolotti

Bignami

Rossi

et al. 2021

J Thromb Thrombolysis

View full text Add to dashboard Cite

Covid-19 associated autoimmune thrombotic thrombocytopenic purpura: Report of a case

Cited by 55 publications

References 10 publications

COVID-19 associated thrombotic thrombocytopenic purpura (TTP) ; A case series and mini-review

COVID-19 associated thrombotic thrombocytopenic purpura (TTP) ; A case series and mini-review

Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation

A case of thrombotic thrombocytopenic purpura associated with COVID-19

Contact Info

Product

Resources

About